ADMA Biologics (ADMA) Reports Q2 Loss of $0.35/Share

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.35), versus ($0.55) reported last year. Revenue for the quarter came in at $4.7 million, versus $3.4 million reported last year.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• TRNR agrees to acquire STEPR, raises 2026 revenue guidance to $50M